Evidence map›Paper›PMID 35086559›Full record

ArticleGenome medicine2022

Genome-scale CRISPR screens identify host factors that promote human coronavirus infection.

Marco Grodzki, Andrew P Bluhm, Moritz Schaefer, Abderrahmane Tagmount, Max Russo, Amin Sobh, Roya Rafiee, Chris D Vulpe, Stephanie M Karst, Michael H Norris

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. SARS-CoV-2 biology and host interactions.Nature reviews. Microbiology · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Marco GrodzkiDepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA.
Andrew P BluhmDepartment of Geography, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, USA.
Moritz SchaeferDepartment of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Abderrahmane TagmountDepartment of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Max RussoDepartment of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Amin SobhUniveristy of Florida Heath Cancer Center, University of Florida, Gainesville, FL, USA.
Roya RafieeDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Chris D VulpeDepartment of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Stephanie M KarstDepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA. skarst@ufl.edu.ORCID 0000-0003-0406-4637
Michael H NorrisDepartment of Geography, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, USA. mhnorris@ufl.edu.
University of Florida · USUniversity of Florida Health · US

Funding

Identification of Host and Viral Determinants of Human Norovirus B cell InfectionR01AI123144 · NIAID · UNIVERSITY OF FLORIDA · PI KARST, STEPHANIE M · 2017 to 2021
$2.3M
National Institute of Allergy and Infectious Diseases R01AI123144NIAID NIH HHS R01 AI123144University of Florida Clinical and Translational Science Institute
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has resulted in 275 million infections and 5.4 million deaths as of December 2021. While effective vaccines are being administered globally, there is still a great need for antiviral therapies as antigenically novel SARS-CoV-2 variants continue to emerge across the globe. Viruses require host factors at every step in their life cycle, representing a rich pool of candidate targets for antiviral drug design.

methodsTo identify host factors that promote SARS-CoV-2 infection with potential for broad-spectrum activity across the coronavirus family, we performed genome-scale CRISPR knockout screens in two cell lines (Vero E6 and HEK293T ectopically expressing ACE2) with SARS-CoV-2 and the common cold-causing human coronavirus OC43. Gene knockdown, CRISPR knockout, and small molecule testing in Vero, HEK293, and human small airway epithelial cells were used to verify our findings.

resultsWhile we identified multiple genes and functional pathways that have been previously reported to promote human coronavirus replication, we also identified a substantial number of novel genes and pathways. The website https://sarscrisprscreens.epi.ufl.edu/ was created to allow visualization and comparison of SARS-CoV2 CRISPR screens in a uniformly analyzed way. Of note, host factors involved in cell cycle regulation were enriched in our screens as were several key components of the programmed mRNA decay pathway. The role of EDC4 and XRN1 in coronavirus replication in human small airway epithelial cells was verified. Finally, we identified novel candidate antiviral compounds targeting a number of factors revealed by our screens.

conclusionsOverall, our studies substantiate and expand the growing body of literature focused on understanding key human coronavirus-host cell interactions and exploit that knowledge for rational antiviral drug development.

Indexed as

Genome, ViralAnimalsAntiviral AgentsChlorocebus aethiopsClustered Regularly Interspaced Short Palindromic RepeatsCOVID-19COVID-19 Drug TreatmentExoribonucleasesGene EditingHEK293 CellsHost-Pathogen InteractionsHumansMicrotubule-Associated ProteinsProteinsRNA, Guide, CRISPR-Cas SystemsRNA InterferenceAntiviral AgentsEDC4 protein, humanExoribonucleasesMicrotubule-Associated ProteinsProteinsRNA, Guide, CRISPR-Cas SystemsRNA, Small InterferingXRN1 protein, human

Identifiers

PMID35086559
PMCPMC8792531
OpenAlexW4221065624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.